Scinai Immunotherapeutics' PC111 Breakthrough Recognized with Top Italian Dermatology Award
TL;DR
Scinai Immunotherapeutics gains a competitive edge with Dr. Roberta Lotti's award-winning research on PC111, a potential breakthrough for autoimmune skin conditions.
PC111, developed by Pincell Srl and optioned by Scinai, works by blocking soluble Fas Ligand to prevent blister formation in pemphigus vulgaris.
The advancement of PC111 by Scinai Immunotherapeutics offers hope for a non-immunosuppressive treatment, improving lives affected by severe autoimmune skin diseases.
Discover how Scinai Immunotherapeutics is pioneering a novel treatment for pemphigus vulgaris with PC111, a first-in-class anti-Fas Ligand monoclonal antibody.
Found this article helpful?
Share it with your network and spread the knowledge!
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced a significant milestone in the development of PC111, a first-in-class anti-Fas Ligand monoclonal antibody, following Dr. Roberta Lotti of Pincell Srl receiving the "Oscar of Italian Dermatology" from SIDeMaST. This accolade highlights the groundbreaking research published under the title "Blocking soluble Fas Ligand ameliorates pemphigus", which demonstrates PC111's efficacy in preventing blister formation by inhibiting keratinocyte apoptosis in pemphigus vulgaris, a severe autoimmune skin condition.
The recognition of Dr. Lotti's work not only validates the scientific community's interest in PC111 but also marks a pivotal moment for Scinai Immunotherapeutics as it advances PC111 as a lead asset. The company holds an option to acquire Pincell, further solidifying its commitment to developing innovative treatments for inflammation and immunology-related diseases. PC111's potential as a non-immunosuppressive, disease-modifying therapy offers hope for patients suffering from severe autoimmune skin conditions, representing a significant advancement in dermatological treatment options.
For more details on the research and the award, visit https://ibn.fm/51v14.
Curated from InvestorBrandNetwork (IBN)
